Huayu Pharmaceutical focuses on cancer neuromedical medical materials
Chen Zheng (right), chairman of Uni Pharma, and Lin Liangguang (left), general manager, took a group photo. Photo/Zhang Bingfeng
Founded 18 years ago, Huayu Pharmaceutical (6621) is a small and medium-sized biotechnology medical industry focusing on the development of tumor detection, tumor ablation, next-generation neuromedical biomarkers and oncology-related new drug development, focusing on the two major fields of cancer and neuromedicine, and is committed to providing personalized, affordable and considerate medical services through the team’s professional and innovative products.
Chen Zheng, chairman of Uni Pharma, said that Huayu Pharmaceutical is a boutique company, with unique products and technologies to solve characteristic medical problems, has a monopoly position in the market, first seek to make money steadily, after entering the capital market, so that shareholders can at least maintain a stable dividend yield income, medium and long-term layout and development of characteristic new drugs, new medical materials, accumulate the explosive energy of this small diamond, and look forward to the future to shine.
Chen Zheng said that in June last year, the Ministry of Health and Welfare approved Huayu Pharmaceutical’s first new ingredient and new drug, Kang Lijie, which is an antidote to methanol or ethylene glycol poisoning; Kang Li Alcohol Dehydrogenase Inhibitor Pharmacology Transfer, can develop new drugs related to alcohol and cancer, Asian yellow people gene lack aldehyde dehydrogenase, long-term drinking is easy to accumulate acetaldehyde will increase the risk of cancer and liver disease, about one in two Taiwanese is aldehyde dehydrogenase gene deficiency, the highest risk of drinking in the world.
Huayu Pharmaceutical continues to develop Kang Li Jie’s new oral drug, which can reduce esophageal cancer and liver cancer caused by alcohol consumption, and last year, the new oral drug has applied for IND to the Ministry of Health and Welfare, targeting the yellow market. In addition, Kang Li Xie has developed new drugs for alcohol abstinence, and plans to apply for IND next year, targeting Caucasians with active aldehyde dehydrogenase. The market size of these two types of drugs ranges from tens of millions of dollars to hundreds of millions of dollars, and they are the products of Huayu Pharmaceutical’s medium and long-term layout.
This year, Huayu Pharmaceutical will expand its product portfolio with tumor-centered tumor monitoring system (DR-70 and EZ Detect), RFA tumor ablation system and anti-cancer drug blood concentration monitoring system to expand business competitiveness and improve R&D capabilities and brand value.
DR-70 is a new generation of colorectal cancer recurrence tracking reagent, which has better sensitivity and specificity than existing products, and has passed FDA, CE and TFDA certifications. This year, it will actively expand the markets of Taiwan, Turkey, India, Thailand, Indonesia and other markets, complete CFDA clinical trials, and submit new diagnostic reagent products for registration.
The company plans to develop new specifications of DR-70 reagents and second-generation products suitable for automated models.
RFA tumor ablation system is a safe, minimally invasive, effective, low-pain tumor treatment plan, suitable for the liver, kidney, lung or other organs in the abdominal cavity tumor tissue, RFA minimally invasive surgery can avoid facial scarring, about 12,000 to 15,000 patients in China every year. RFA is an important source of revenue for Huayu Pharmaceutical, and its future growth momentum is promising.
(Business Times)
